
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.67186
Pharmacology
Neurology
Emergency Medicine
Intravenous Tenecteplase for Acute Ischemic Stroke During Active Menstruation
Muacevic Alexander
Adler John R
Baisden Nathan A 1
Preston Jordan 1
Nolte Justin 1
Adams Jason 1
1 Neurology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA
Nathan A. Baisden baisden77@marshall.edu
19 8 2024
8 2024
16 8 e6718618 8 2024
Copyright © 2024, Baisden et al.
2024
Baisden et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/276489-intravenous-tenecteplase-for-acute-ischemic-stroke-during-active-menstruation
We report a case of a 51-year-old female who presented to the emergency department with stroke symptoms within the time window for intravenous (IV) thrombolytic therapy. Her initial CT head imaging showed no evidence of acute changes and her CT perfusion demonstrated an area of ischemia in the left parieto-occipital region. While she had no absolute contraindications for IV tenecteplase (TNK), she was actively menstruating at the time, which could represent a relative contraindication due to increased bleeding risk from a site that would not be easily compressible. She elected to receive TNK and did not experience any adverse events after treatment was administered. At her follow-up clinic visit, her neurological deficits were completely resolved.

In the context of increasingly widespread usage of TNK, this case report highlights an uncommon but important consideration when treating acute ischemic strokes with IV thrombolytic in the female population. While no definitive conclusions should be drawn from this case, it would hopefully encourage the continued usage of TNK in menstruating females who present with stroke symptoms within the therapeutic window and with no other contraindications.

female reproductive
stroke thrombectomy
young adult ischemic stroke
alteplase (tpa)
stroke
: ischemic stroke
menses
tenecteplase (tnk)
==== Body
pmcIntroduction

While it is well known that recent gastrointestinal hemorrhage and a history of intracranial hemorrhage are contraindications to intravenous (IV) thrombolysis in an acute ischemic stroke setting [1], there is scarce literature on patients who are currently menstruating. Case reports and the original NINDS trial indicate that IV alteplase can be used safely for an acute ischemic stroke in this population [2]. Due to the age at which most females present with strokes, there is a lack of widespread studies on the subject. The most current American Heart Association and American Stroke Association (AHA/ASA) guidelines state that “IV alteplase is probably indicated in women who are menstruating who present with acute ischemic stroke and do not have a history of menorrhagia. However, women should be warned that alteplase treatment could increase the degree of menstrual flow.” [3]

Tenecteplase (TNK) has been recently approved by the AHA/ASA for an acute ischemic stroke [3]; however, little is known about the systemic administration of this agent in females who present within the time window for an acute ischemic stroke and are currently menstruating. The ASSENT-2 trial, which compared outcomes of IV-administered TNK vs. alteplase for acute coronary syndrome (ACS), showed fewer non-cerebral bleeding complications and less need for blood transfusions when using TNK [4]. A subsequent meta-analysis of three clinical trials, again for ACS, demonstrated a statistically significant reduction in major bleeding risk with TNK compared to alteplase [5]. The dosing of TNK for acute ischemic stroke is different than it is for ACS. For ischemic stroke, TNK is dosed at either 0.25 mg/kg (max dose: 25 mg) or 0.4 mg/kg, and for ACS, it is more commonly dosed in weight intervals, but with a maximum dose of 50 mg [3,6]. While the above information is promising for the use of TNK in menstruating females presenting with acute ischemic stroke, it is difficult to extrapolate the ACS data for this specific patient population.

Given the above information, we thought that it would be pertinent to discuss a case of a menstruating female involving the use of IV TNK for an acute ischemic stroke, who met all other criteria for its administration. In this case, TNK was dosed at 0.25 mg/kg (max dose: 25 mg) as previous clinical trials showed no benefit with higher dosing [7]. We hope that this report will encourage continued aggressive usage of this agent in acute ischemic strokes when determined to be of benefit.

Case presentation

A 51-year-old female presented to the emergency department as a prehospital stroke alert with right facial droop, right arm and leg weakness, right-sided sensory loss, and dysarthria. Her last known well had been 51 minutes before arrival. The National Institute of Health Stroke Scale (NIHSS) score was 6 and the Modified Rankin Score (MRS) was 4, indicating moderately severe disability. The patient's past medical history was relevant for a history of two previous strokes in the right basal ganglia and right frontal lobe with residual weakness on the left side. Stroke risk factors included hypertension, diabetes, hyperlipidemia, and tobacco usage. Her blood pressure was 190/120 mmHg and her blood glucose was 150 mg/dL. CT head showed no acute changes (Figure 1). CT perfusion showed left parieto-occipital ischemia (Figure 2).

Figure 1 CT head upon presentation

The image shows no evidence of intracranial hemorrhage or completed infarct compatible with current symptoms. There was evidence of a previous infarction of the right basal ganglia as reported in prior history

CT: computed tomography

Figure 2 CT angiography perfusion showing mean transit time (A) and cerebral blood volume (B)

A. Demonstrates an area of increased mean transit time in the left parieto-occipital region. B. Demonstrates no increased signal on cerebral blood volume imaging in the same area. This indicates an area of ischemic penumbra in this region

CT: computed tomography

The patient stated she was menstruating but denied heavy flow or a history of dysfunctional bleeding. Blood pressure remained above the cutoff of 185/110 mmHg for thrombolytic but improved with IV labetalol. The risks and benefits of TNK were discussed, and she elected for treatment despite menstrual bleeding. The patient was not a thrombectomy candidate as there was no evidence of large vessel occlusion on CT angiography; 24-hour post-TNK CT head showed no evidence of hemorrhagic transformation (Figure 3). The patient was subsequently started on aspirin 81 mg daily. No increase in menstrual bleeding was reported by the patient. She showed improvement in her symptoms with NIHSS and MRS of 0 upon discharge to an inpatient rehabilitation facility.

Figure 3 24-hour post-TNK CT head imaging showing no evidence of hemorrhagic transformation

CT: computed tomography; TNK: tenecteplase

She presented to the neurology clinic for follow-up after discharge from the rehabilitation facility. At her one-month follow-up, she had no right-sided motor or sensory deficits. She did have continued weakness and sensory loss in her left face, arm, and leg consistent with residual deficits from her two prior strokes. She endorsed compliance with aspirin and atorvastatin. Her blood pressure was within normal range, and she reported working with her primary care provider to attain better glycemic control. She continued to smoke cigarettes but endorsed a willingness to work toward cessation. She failed to show up for her three-month post-stroke follow-up and was subsequently lost to follow-up thereafter.

Discussion

While TNK is increasingly being used for systemic IV thrombolytic therapy of acute ischemic strokes, there is a dearth of data on its use in women who are actively menstruating. Menstruation is not listed as a contraindication for thrombolytic therapy in acute ischemic strokes; however, a recent genitourinary hemorrhage is listed as a relative contraindication [1]. While premenopausal women have an increased risk for stroke [8], it is a rarer phenomenon in menstruating patients. This is likely due to the infrequency of menstruation, occurring approximately every 28 days. It is also known that the risk of stroke increases with age, and hence most ischemic stroke patients are past the point of menstruation [8]. Post-menopausal bleeding is a common phenomenon, but due to time constraints for administering thrombolytic, no distinction was made in this case other than the history that was obtained from the patient. Based on her reporting, the bleeding she was experiencing was a part of her normal menstrual cycle and genitourinary hemorrhaging was ruled out.

TNK is a recombinant DNA-derived version of tissue plasminogen activator which differs from alteplase given its higher affinity for the fibrin component of a thrombus. It also exhibits a greater resistance to inactivation by endogenous plasminogen activator inhibitors, resulting in a longer half-life [9]. These properties are linked to TNK's superior performance over alteplase when treating large vessel strokes in clinical trials [10]. Subsequent analysis showed that TNK was non-inferior to alteplase for all acute ischemic stroke subtypes. Further, TNK was not associated with an increased risk of subsequent symptomatic intracranial hemorrhaging [11]. This, along with the ease of administration in a single bolus, has led to TNK gaining favorability in recent years in the treatment of acute ischemic strokes [12].

Our patient had a history of multiple strokes with residual deficits. It was felt to be in her best interest to treat the current ischemic stroke with thrombolytic therapy as she did not show any evidence of a large vessel occlusion on CT angiography which would have been amenable to mechanical thrombectomy. She was informed of the risk of increased bleeding with systemic TNK but still elected for treatment to prevent further disability. She did not experience any adverse effects and saw the resolution of her right-sided deficits before discharge.

Conclusions

We discussed a case of a 51-year-old female who was actively menstruating with disabling stroke symptoms and was successfully treated with IV TNK with no reportable side effects and specifically no reported increase in menstrual blood flow. Current genitourinary bleeding is a relative contraindication to IV thrombolysis for an acute ischemic stroke. Shared decision-making between the treating provider and the patient, or their surrogate decision maker, is always encouraged when choosing IV thrombolytic therapy to treat an acute ischemic stroke. While no definitive recommendations can be made based on this case, it would hopefully inspire further analysis on this subject.

Disclosures

Author Contributions

Human subjects: Consent was obtained or waived by all participants in this study. Marshall University Institutional Review Board #1 issued approval 2215677-1.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Nathan A. Baisden, Jordan Preston

Acquisition, analysis, or interpretation of data:  Nathan A. Baisden, Jordan Preston, Justin Nolte, Jason Adams

Drafting of the manuscript:  Nathan A. Baisden, Jordan Preston

Critical review of the manuscript for important intellectual content:  Nathan A. Baisden, Jordan Preston, Justin Nolte, Jason Adams

Supervision:  Justin Nolte, Jason Adams
==== Refs
References

1 Absolute and relative contraindications to IV rt-PA for acute ischemic stroke Neurohospitalist Fugate JE Rabinstein AA 110 121 5 2015 26288669
2 Safety of tissue plasminogen activator for acute stroke in menstruating women Stroke Wein TH Hickenbottom SL Morgenstern LB Demchuk AM Grotta JC 2506 2508 33 2002 12364745
3 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke Powers WJ Rabinstein AA Ackerson T 0 418 50 2019
4 Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial Lancet Van De Werf F Adgey J Ardissino D 716 722 354 1999 10475182
5 Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials Arch Med Sci Guillermin A Yan DJ Perrier A Marti C 1181 1187 12 2016 27904506
6 Tenecteplase StatPearls 7 2024 Bach KT Lui F Treasure Island, FL StatPearls Publishing 2023 https://www.ncbi.nlm.nih.gov/books/NBK592420/
7 Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients With large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial JAMA Campbell BC Mitchell PJ Churilov L 1257 1265 323 2020 32078683
8 Stroke: causes and clinical features Medicine (Abingdon) Murphy SJ Werring DJ 561 566 48 2020 32837228
9 Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction Clin Pharmacokinet Tanswell P Modi N Combs D Danays T 1229 1245 41 2002 12452736
10 Tenecteplase versus alteplase before thrombectomy for ischemic stroke N Engl J Med Campbell BC Mitchell PJ Churilov L 1573 1582 378 2018 29694815
11 Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials Stroke Vasc Neurol Xiong Y Wang L Li G 8 10 6 2023
12 Using tenecteplase for acute ischemic stroke: what is the hold up? West J Emerg Med Zitek T Ataya R Brea I 199 202 21 2020 32191176
